Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project

Citation
G. Da Villa et al., Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project, RES VIROL, 149(5), 1998, pp. 263-270
Citations number
12
Categorie Soggetti
Microbiology
Journal title
RESEARCH IN VIROLOGY
ISSN journal
09232516 → ACNP
Volume
149
Issue
5
Year of publication
1998
Pages
263 - 270
Database
ISI
SICI code
0923-2516(199809/10)149:5<263:LESOHB>2.0.ZU;2-Q
Abstract
In 1983, a pilot project of universal hepatitis B vaccination was introduce d in a hyperendemic area in southern Italy (Afragola) and is ongoing to dat e. In this area before the start of vaccination, we found significant evide nce of HBV endemicity: the acute viral hepatitis B incidence in the general population averaged 63/100,000; the HBsAg and anti-HBc prevalence rates we re 13.4% and 66.9%, respectively; there was involvement of hepatitis B viru s (HBV) in 48.1% of chronic liver pathologies (46.3% in chronic viral hepat itis, 49.5% in cirrhosis and 71.7% in hepatocellular carcinoma cases). We s tudied the acute viral hepatitis incidence during the vaccination period fr om 1983 to 1997 and compared the HBsAg and anti-HBc prevalences in 1978 to those in 1997, after 15 years of vaccination. The HBV-related chronic patho logy prevalence was also studied. We found a remarkable drop in the acute v iral hepatitis incidence, from an average annually of 63/100,000 in the fiv e years before vaccination to 3/100,000 in the last five years of vaccinati on. In addition, the HBsAg carrier prevalence in the general population dec reased from 13.4% in 1978 to 3.7% in 1997. The percentage dropped in childr en and adolescents from 6.8% to 0.7%, in young people from 10.2% to 1.1% an d in adults from 15.8% to 4.0%. The anti-HBc carrier prevalence, found to b e 66.9% in 1978, was 34.2% in 1997. Finally, we found a much less significa nt involvement of HBV in chronic liver pathologies; in fact, it was present in only 18.2% of cases in 1997 and in 48.2% in 1982. In the light of the d ata, we can assert that universal hepatitis B vaccination has had a substan tial effect on HBV endemicity in the Afragola area. We believe that the red uction found in the incidence of acute viral hepatitis B and HBV-related ch ronic liver pathologies is connected to the decrease in HBV carriers in the area, which therefore reduces the risk of contagion for the unvaccinated.